https://doi.org/10.4081/monaldi.2021.1646
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19
Supplementary: 175
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
There is limited evidence describing the safety and effectiveness of bedaquiline and delamanid containing regimens in children and adolescents with Multidrug-Resistant Tuberculosis (MDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) globally. In this nationwide descriptive cohort study from Belarus, we examined adverse drug events, time to culture conversion, treatment outcomes including post-treatment recurrence among children and adolescents (<18 years of age) treated with bedaquiline and/or delamanid containing regimens from 2015 to 2019. Of the 40 participants included (55% females; age range 10-17 years), 20 (50%) had XDR-TB and 15 (38%) had resistance to either fluoroquinolone or second-line injectable. Half of the patients received delamanid and another half received bedaquiline with one patient receiving both drugs. AEs were reported in all the patients. A total of 224 AEs were reported, most of which (76%) were mild in nature. Only 10 (5%) AEs were graded severe and one AE was graded life-threatening. A total of 7 AEs (3%) were classified as ‘serious’ and only one patient required permanent discontinuation of the suspected drug (linezolid). Most of the AEs (94%) were resolved before the end of treatment. All patients culture-positive at baseline (n=34) became culture-negative within three months of treatment. Median time to culture conversion was 1.1 months (interquartile range: 0.9-1.6). Two patients were still receiving treatment at the time of analysis. The remaining 38 patients successfully completed treatment. Among those eligible and assessed at 6 (n=32) and 12 months (n=27) post-treatment, no recurrences were detected. In conclusion, treatment of children and adolescents with MDR-TB and XDR-TB using bedaquiline and/or delamanid containing regimens was effective and had favourable safety profile. Achieving such excellent outcomes under programmatic settings is encouraging for other national tuberculosis programmes, which are in the process of introducing or scaling-up the use of these new drugs in their countries.
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- M. Irfan, F. Thiavalappil, J. Nagaraj, T.H. Brown, D. Roberts, L. Mcknight, N.K. Harrison, Tuberculous pancreatitis complicated by ruptured splenic artery pseudoaneurysm , Monaldi Archives for Chest Disease: Vol. 79 No. 3-4 (2013): Pulmonary series
- B. Uskul, H. Turker, C. Ulman, M. Ertugrul, A. Selvi, A. Kant, S. Arslan, M. Ozgel, The relation of the pleural thickening in tuberculosis pleurisy with the activity of adenosine deaminase , Monaldi Archives for Chest Disease: Vol. 63 No. 2 (2005): Pulmonary series
- W.O. Tam, C.F. Wong, P.C. Wong, Endobronchial Nocardiosis associated with Broncholithiasis , Monaldi Archives for Chest Disease: Vol. 69 No. 4 (2008): Pulmonary series
- Carlos A. Jiménez-Ruiz, Marcos Garcia Rueda, Manuel A. Martinez Muñiz, Jacobo Sellarés, Maria A. Jiménez-Fuentes, Lourdes Lázaro Asegurado, Esther RodrÃguez Gonzalez, Concepción Rodriguez Garcia, Oriol Armengol, Emilia Abad, Teresa Peña, Adolfo Domenech del Rio, Juan A. Riesco Miranda, Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study , Monaldi Archives for Chest Disease: Vol. 87 No. 3 (2017)
- P.D.O. Davies, Risk factors for tuberculosis , Monaldi Archives for Chest Disease: Vol. 63 No. 1 (2005): Pulmonary series
- Jyothish K, Jawahar Lal Joshi, Heena Kansal, Vishal Chopra, Kranti Garg, Nidhi Girdhar, Karan Sharma, Rishabh Deshwal, Siddharth Sharma, Association of IL4RA and IL-8 polymorphism in predicting susceptibility to tuberculosis , Monaldi Archives for Chest Disease: Vol. 94 No. 2 (2024)
- Govind Desai, Gopal Purohit, Hemant Borana, Kunal Deokar, Suresh Yogi, Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Princy Domnic Dsouza, Sai Phalguna Prakash Chitralu, Chandrashekhar Mallikarjun Patil, Vinod Ashok Koujalagi, Sanatkumar Bharamu Nyamagoud, Prescription patterns and drug utilization in respiratory tract infections: implications for antimicrobial stewardship at a tertiary care teaching hospital , Monaldi Archives for Chest Disease: Early Access
- Deepak Sharma, Vinay V, Jitendra Kumar Saini, Prabhpreet Sethi, Sandeep Jain, Kumar Puskar, Elucidating diagnostic efficacy and safety of the procedure: cryobiopsy of endobronchial lesions with a flexible bronchoscope , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- Debapriya Maji, Upasna Agarwal, Lokender Kumar, Vinay V, Amit Sharma, Clinicodemographic profile and outcome of tuberculosis treatment in TB-HIV co-infected patients receiving daily ATT under a single window TB-HIV services delivery initiative , Monaldi Archives for Chest Disease: Vol. 93 No. 3 (2023)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
